KNIGHT IS ON THE RIGHT PATH
We believe Knight is on the right path, patiently executing a strategy that Jonathan has proven works. At Paladin, Jonathan showed that a successful company in this industry can be steadily built by laying a solid foundation for sustainable profitable growth without having to take big unnecessary binary risks.
That is why we are so confident the best is yet to come and why we at Knight never rest.
Jonathan founded Knight with a vision to build a leading specialty pharmaceutical company in Canada and select international markets, to make a meaningful difference in the lives of patients, and, in the process deliver healthy returns to our shareholders.
Our team is delivering on these goals. In 2018, year-over-year revenue and net income increased by 45% and 40% respectively and, as at December 31, 2018, Knight had over $787 million in cash, cash equivalents, and marketable securities.
We have also performed well compared with similar companies. Knight has generated more net income since its inception than any other specialty pharmaceutical company in Canada and, in the 1- and 3-year periods—and since IPO—we have outperformed our peers. We’re not resting on our laurels.
With our strong balance sheet, we will focus on profitable growth through in-licensing of pharmaceutical products for Canadian and select international markets. In addition, we continue to explore corporate acquisitions but will only execute at a fair price.
We will also continue to pursue strategic loans and equity investments to secure rights to innovative pipeline assets, including early stage products, and we’re advancing our rest-of-the-world strategy, identifying the right strategic partners in Latin America, the Middle East and Africa.
We believe that this proven, responsible and disciplined strategy best positions us to maximize shareholder value, in both the short- and long-term.